Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1719558

registered interest
date	21/05/2024
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to help support scientists to transition to animal-free, human-specific technologies through (a) practical support, (b) the provision of training and (c) other means.
tabling member constituency	Worthing West
tabling member printed	Sir Peter Bottomley
uin	27237
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>The Government, via UK Research &amp; Innovation, funds the development of techniques that replace, reduce and refine the use of animals in research through the National Centre for 3Rs (NC3Rs). The NC3Rs encourages researchers’ to use non-animal methods (NAMs) in a number of ways, including supporting the skills base by funding PhD students to work only on the development of NAMs, and dedicated funding allowing researchers to test methods alongside existing animal studies. NC3Rs recently launched a network to bring researchers from academia, industry and regulatory authorities together to share knowledge on the use of NAMs methods for safety testing.</p> answering member constituency Arundel and South Downs answering member printed Andrew Griffith question first answered 24/05/2024 09:09:32 answering member 4874 label Biography information for Andrew Griffith
tabling member	117 label Biography information for Sir Peter Bottomley

1719559

registered interest
date	21/05/2024
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, if she will make an assessment of the potential merits of hosting a global summit on human-specific technologies for scientists and policymakers to discuss the transition to these methodologies.
tabling member constituency	Worthing West
tabling member printed	Sir Peter Bottomley
uin	27238
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>The UK works closely with international partners and key organisations such as the Organisation for Economic Co-operation and Development (OECD) to promote the development and uptake of animal replacement technologies. There are currently no plans to host a summit on the matter.</p> answering member constituency Arundel and South Downs answering member printed Andrew Griffith question first answered 24/05/2024 09:10:31 answering member 4874 label Biography information for Andrew Griffith
tabling member	117 label Biography information for Sir Peter Bottomley

1683035

registered interest
date	17/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support the research and development of medical technologies in the UK.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	10125
answer	answer is ministerial correction date of answer 23/01/2024 answer text <p>The Department-funded National Institute for Health and Care Research (NIHR) funds research to develop medical technologies through its research programmes, primarily the invention for innovation programme. This programme provides funding to industry and researchers to develop innovative healthcare technologies, including medical devices, which address existing or emerging health and social care needs. The NIHR also supports the development of medical technologies through its research infrastructure, primarily the Medtech and In Vitro Diagnostic Co-operatives, which will be replaced with the NIHR HealthTech Research Centres (HRCs) from 1 April 2024. The 14 NIHR HRCs will work with industry and researchers to support the whole pathway from development of medical devices, diagnostics and digital technologies, through to adoption in the health and care system.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/01/2024 14:44:35 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4124 label Biography information for Chi Onwurah

1670317

registered interest
date	15/11/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, whether her Department provided funding for biomedical research using (a) live animals and (b) non-animal for (i) organ-on-a-chip, (ii) computer modelling and (iii) other technologies in the period between 1 January 2022 and 31 December 2022.
tabling member constituency	Warrington North
tabling member printed	Charlotte Nichols
uin	2218
answer	answer is ministerial correction date of answer 24/11/2023 answer text <p>Government funds biomedical and biological research using animals and non-animal methodologies and technologies, recognising that the highly regulated and limited use of animals in scientific procedures remains necessary for understanding how biological systems work, in the development of new medicines, treatments and technologies, and for testing chemicals to protect human health and the environment. UKRI funds research and innovation aimed at reducing or eliminating the use of animals in research, providing approximately £10m per annum for the world-leading National Centre for the Replacement, Refinement and Reduction of Animals in Research to drive the development and uptake of 3Rs technologies – including organ-on-a chip and computer modelling.</p> answering member constituency Arundel and South Downs answering member printed Andrew Griffith question first answered 24/11/2023 10:05:03 answering member 4874 label Biography information for Andrew Griffith
tabling member	4799 label Biography information for Charlotte Nichols

1655151

registered interest
date	25/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicine: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what resource commitment they are providing to enable the translation of medical research into implementation in practice.
tabling member printed	Lord Weir of Ballyholme
uin	HL9730
answer	answer is ministerial correction date of answer 31/07/2023 answer text <p>The National Institute for Health and Care Research (NIHR) puts high quality research evidence at the heart of decision making in the National Health Service, public health, and social care. Through research, the NIHR helps policy makers, health &amp; care professionals and patients make evidence-based decisions about which treatments and practices are most effective and which make best use of resources.</p><p>In 2022/23, the NIHR’s budget was approximately £1.25 billion, and resourcing to enable translation of research into practice is embedded across multiple workstreams in the NIHR portfolio. Through the Centre for Engagement and Dissemination, the NIHR also leads and coordinates activities which support the translation of NIHR evidence into practice, at a total five-year contract value of approximately £9.8 million.</p> answering member printed Lord Markham question first answered 31/07/2023 13:54:48 answering member 4948 label Biography information for Lord Markham
tabling member	4970 label Biography information for Lord Weir of Ballyholme

1651745

registered interest
date	10/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the debate of 4 July on Human-specific medical research techniques, Official Report columns 293WH to 304WH, what assessment he has made of the capability of the UK’s regulatory system to support the (a) development and (b) use of human-specific technologies in medical research.
tabling member constituency	Glasgow Central
tabling member printed	Alison Thewliss
uin	193164
answer	answer is ministerial correction date of answer 13/07/2023 answer text <p>As the regulator of medicines, medical devices and blood components for transfusion in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) keeps abreast of advances in human-specific technologies in medical research that are relevant to the development of medicines and medical devices. The MHRA is aware of human-specific techniques, such as organ-on-chip technologies used to better identify potential toxicity of novel medicines, and has engaged with other organisations active in this space such as the National Centre for the Replacement, Refinement &amp; Reduction of Animals in Research who have hosted meetings on this theme. The MHRA has also provided scientific advice on the use of this technology to support proof of concept for a new medicine. That said, the MHRA does not identify those with whom it may have had discussions who are active commercially in this space.</p><p>In relation to human-specific technologies, some medicines have been developed which only have activity in humans, such as eculizumab (Soliris), tebentafusp (Kimmtrak) or CAR T cell products (for instance, Kymriah, Yescarta and Tecartus). These medicines were developed using human specific methods, however, versions of these medicines that were active in animals were, in some cases, also used. The MHRA supports the developers of these products by its offer of scientific advice services, the Innovation Office and the Innovative Licensing and Access Pathway.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/07/2023 16:45:35 answering member 4423 label Biography information for Will Quince
tabling member	4430 label Biography information for Alison Thewliss

1587406

registered interest
date	20/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicine: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have (1) to deliver their clinical research vision, and (2) to provide funding to support the growth of the UK’s phase 1 trial capacity.
tabling member printed	Lord Hunt of Kings Heath
uin	HL5678
answer	answer is ministerial correction date of answer 06/03/2023 answer text <p>The Future of UK Clinical Research Delivery 2022-2025 implementation plan summarises the progress made in 2021-22 towards delivering the vision and the actions that are being taken by the various delivery partners (the National Institute for Health and Care Research (NIHR), NHS England, the Medicines and Healthcare products Regulatory Agency, Health Research Authority and Devolved Administrations) between 2022 and 2025 to make progress to achieve our vision in full by 2031. This plan is being delivered under the UK Recovery, Resilience and Growth Programme.</p><p> </p><p>To support the growth of phase 1 trial capacity the NIHR has confirmed an investment of £969 million over the next five years in its early translational research infrastructure, which includes the NIHR Biomedical Research Centres, NIHR Clinical Research Facilities and NIHR/Cancer Research UK Experimental Cancer Medicine Centres.</p> answering member printed Lord Markham question first answered 06/03/2023 11:56:40 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1519464

registered interest
date	10/10/2022
answering body	Prime Minister
answering dept id	23
answering dept short name	Prime Minister
answering dept sort name	Prime Minister
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Prime Minister, if she will make an assessment of the potential merits of appointing a Minister for Human Relevant Science to be tasked with accelerating the take-up of innovative medical research techniques such as the use of artificial intelligence and organ-on-a-chip technology.
tabling member constituency	Liverpool, Riverside
tabling member printed	Kim Johnson
uin	60159
answer	answer is ministerial correction date of answer 18/10/2022 answer text <p>My hon. Friend, the Member for Wealden (Nusrat Ghani), is the Minister of State (Minister for Science and Investment Security) at the Department for Business, Energy and Industrial Strategy. A summary of her responsibilities can be found on gov.uk here:</p><p><a href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fministers%2Fminister-of-state-minister-for-science-and-investment-security&amp;data=05%7C01%7CAO%27malley%40no10.gov.uk%7C935ecba7319242509b0e08dab03aa460%7C29c8cbb9d9af4c7eb28b470f15275e47%7C1%7C0%7C638016063158787638%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=FpWxsM8Q5Xc1LvkVI%2FSLDPZwEkZQFc6eExz%2FrZWrEUw%3D&amp;reserved=0" target="_blank">Minister of State (Minister for Science and Investment Security) - GOV.UK (www.gov.uk)</a>.</p> answering member constituency South West Norfolk answering member printed Elizabeth Truss question first answered 18/10/2022 15:12:07 answering member 4097 label Biography information for Elizabeth Truss
tabling member	4824 label Biography information for Kim Johnson

1488056

registered interest
date	11/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will meet with his counterparts in the Devolved nations to discuss the role of clinical research in (a) driving better patient outcomes ad (b) fostering better innovative treatments for patients.
tabling member constituency	Kirkcaldy and Cowdenbeath
tabling member printed	Neale Hanvey
uin	33944
answer	answer is ministerial correction date of answer 26/07/2022 answer text <p>We continue to meet regularly with the devolved administrations to discuss clinical research in the United Kingdom. ‘The Future of UK Clinical Research Delivery: 2022 to 2025 implementation plan’ has been developed by the UK Government and the devolved administrations in collaboration with the clinical research community and delivery partners through the UK Clinical Research Recovery Resilience and Growth programme.</p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 26/07/2022 15:57:06 answering member 3992 label Biography information for James Morris
tabling member	4782 label Biography information for Neale Hanvey

1488065

registered interest
date	11/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions the Government has had with (a) representatives of the National Health Systems of the UK and (b) devolved Administrations on developing the Future of UK Clinical Research Delivery 2022 to 2025 implementation plan; and what future discussions he plans to take place to (i) monitor and (ii) evaluate progress made in delivering the agreed actions within the implementation plan.
tabling member constituency	Kirkcaldy and Cowdenbeath
tabling member printed	Neale Hanvey
uin	33945
answer	answer is ministerial correction date of answer 20/07/2022 answer text <p>‘The Future of UK Clinical Research Delivery: 2022 to 2025 implementation plan’ has been developed by the United Kingdom Government and the devolved administrations in collaboration with the clinical research community and delivery partners through the UK Clinical Research Recovery Resilience and Growth (RRG) programme.</p><p>The RRG Oversight Group meets regularly to provide oversight and strategic co-ordination of clinical research delivery in the UK. Members include the UK health departments, Digital Health and Care Wales, National Research Scotland, Health and Social Care Northern Ireland. The implementation plan was published on 30 June 2022 and progress will be monitored and evaluated by the RRG Programme Board and Oversight Group.</p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 20/07/2022 11:12:36 answering member 3992 label Biography information for James Morris
tabling member	4782 label Biography information for Neale Hanvey